$25.81
0[0.00%]
At close: Apr 24
$25.81
0[0.00%]
PreMarket: 4:00PM EDT
Insmed Stock (NASDAQ:INSM), Analyst Ratings, Price Targets, Predictions
Insmed Inc has a consensus price target of $45.47, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Barclays, and Wells Fargo on April 23, 2024, April 11, 2024, and April 1, 2024. With an average price target of $47.67 between Truist Securities, Barclays, and Wells Fargo, there's an implied 84.68% upside for Insmed Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Barclays
Wells Fargo
Guggenheim
UBS
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Insmed
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | INSM | Buy Now | Insmed | $25.81 | 85.97% | Truist Securities | Nicole Germino | → $48 | Initiates | → Buy | Get Alert |
| 04/11/2024 | INSM | Buy Now | Insmed | $25.81 | 54.98% | Barclays | Leon Wang | $37 → $40 | Maintains | Overweight | Get Alert |
| 04/01/2024 | INSM | Buy Now | Insmed | $25.81 | 113.1% | Wells Fargo | Tiago Fauth | $55 → $55 | Maintains | Overweight | Get Alert |
| 02/27/2024 | INSM | Buy Now | Insmed | $25.81 | 109.22% | Guggenheim | Vamil Divan | $52 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | INSM | Buy Now | Insmed | $25.81 | 78.23% | UBS | Trung Huynh | → $46 | Initiates | → Buy | Get Alert |
| 02/15/2024 | INSM | Buy Now | Insmed | $25.81 | 62.73% | Wolfe Research | Andy Chen | → $42 | Initiates | → Outperform | Get Alert |
| 11/20/2023 | INSM | Buy Now | Insmed | $25.81 | 39.48% | JP Morgan | Jessica Fye | → $36 | Reinstates | → Overweight | Get Alert |
| 09/21/2023 | INSM | Buy Now | Insmed | $25.81 | 109.22% | Cantor Fitzgerald | Jennifer Kim | $46 → $54 | Maintains | Overweight | Get Alert |
| 09/19/2023 | INSM | Buy Now | Insmed | $25.81 | 78.23% | Cantor Fitzgerald | Jennifer Kim | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | INSM | Buy Now | Insmed | $25.81 | 62.73% | Evercore ISI Group | Josh Schimmer | $32 → $42 | Maintains | Outperform | Get Alert |
| 09/06/2023 | INSM | Buy Now | Insmed | $25.81 | 43.36% | B of A Securities | Jason Zemansky | $35 → $37 | Maintains | Buy | Get Alert |
| 09/06/2023 | INSM | Buy Now | Insmed | $25.81 | 101.47% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | INSM | Buy Now | Insmed | $25.81 | 101.47% | Guggenheim | Vamil Divan | $50 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | INSM | Buy Now | Insmed | $25.81 | 58.85% | Morgan Stanley | Matthew Harrison | $41 → $41 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | INSM | Buy Now | Insmed | $25.81 | 101.47% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | INSM | Buy Now | Insmed | $25.81 | 93.72% | Guggenheim | Vamil Divan | → $50 | Initiates | → Buy | Get Alert |
| 05/09/2023 | INSM | Buy Now | Insmed | $25.81 | 101.47% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | INSM | Buy Now | Insmed | $25.81 | 78.23% | Cantor Fitzgerald | Jennifer Kim | $49 → $46 | Maintains | Overweight | Get Alert |
| 02/24/2023 | INSM | Buy Now | Insmed | $25.81 | 78.23% | Credit Suisse | Judah Frommer | → $46 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Insmed (INSM)?
The latest price target for Insmed (NASDAQ: INSM) was reported by Truist Securities on April 23, 2024. The analyst firm set a price target for $48.00 expecting INSM to rise to within 12 months (a possible 85.97% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Insmed (INSM)?
The latest analyst rating for Insmed (NASDAQ: INSM) was provided by Truist Securities, and Insmed initiated their buy rating.
When was the last upgrade for Insmed (INSM)?
There is no last upgrade for Insmed.
When was the last downgrade for Insmed (INSM)?
There is no last downgrade for Insmed.
When is the next analyst rating going to be posted or updated for Insmed (INSM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Insmed (INSM) correct?
While ratings are subjective and will change, the latest Insmed (INSM) rating was a initiated with a price target of $0.00 to $48.00. The current price Insmed (INSM) is trading at is $25.81, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.